JAK1 and Splenomegaly: Dual JAK1/2 and ACVR1 inhibition, such as in the case of momelotinib, provides enhanced therapeutic efficacy in MF given that the cardinal features of the disease (anemia, splenomegaly, and systemic symptoms) are concurrently treated with a single agent.